Regulatory

Jun 22, 2016
Highly skilled pharma staff are spending too much time on the routine updating of product information. Technology can free them, writes Dr. Jutta Hohenhörst.
Jun 21, 2016
Rapid growth in Medicare spending on prescription drugs is prompting a leading advisory group to recommend significant revisions in how the government pays for medicines under Part D and Part B
Jun 15, 2016
Despite enthusiasm from payers and pharma companies for innovative drug reimbursement strategies linked to positive patient responses, negotiating such deals is no easy business.
Jun 10, 2016
Sharing un-redacted inspection reports between FDA and EMA may reduce duplicate inspections of facilities.
Jun 09, 2016
Radicals who wield real power at the EMA have gone public with their thinking about the role of regulators in the economic aspects of medicines provision.
Jun 06, 2016
There’s a stampede to relate prices to broader health benefits, but little consensus on how to do so, writes Jill Wechsler.
Jun 03, 2016
California is in the process of potentially establishing a new, disruptive healthcare policy that is proving to be very concerning to the American Rx industry, writes Tom Norton.
Jun 01, 2016
Eleanor Biggs looks at the biggest uncertainties facing the pharma industry if the UK were to leave the EU.
Jun 01, 2016
NHS England head Simon Stevens believes the UK's PPRS needs significantly updating.
May 25, 2016
We desperately need new anti-infective drugs to avoid life threatening infections. Let’s make that happen by punishing companies who don’t invest in R&D for these specific drugs.
native1_300x100
lorem ipsum